EVAg

Variant of the SARS-CoV-2 receptor binding domain (aa 319-591) with mutation L452R. Recombinant protein expressed in Expi293 cells and Streptactin-purified. The protein is equipped with a SpyTag (AHIVMVDAYKPTK) at the C-terminus.

Variant of the SARS-CoV-2 receptor binding domain (aa 319-591) with mutation T478K. Recombinant protein expressed in Expi293 cells and Streptactin-purified. The protein is equipped with a SpyTag (AHIVMVDAYKPTK) at the C-terminus.

Variant of the SARS-CoV-2 receptor binding domain (aa 319-591) with mutation S477N. Recombinant protein expressed in Expi293 cells and Streptactin-purified. The protein is equipped with a SpyTag (AHIVMVDAYKPTK) at the C-terminus.

Variant of the SARS-CoV-2 receptor binding domain (aa 319-591) with mutation E484Q. Recombinant protein expressed in Expi293 cells and Streptactin-purified. The protein is equipped with a SpyTag (AHIVMVDAYKPTK) at the C-terminus.

Variant of the SARS-CoV-2 receptor binding domain (aa 319-591) with mutation E484K. Recombinant protein expressed in Expi293 cells and Streptactin-purified. The protein is equipped with a SpyTag (AHIVMVDAYKPTK) at the C-terminus.

Variant of the SARS-CoV-2 receptor binding domain (aa 319-591) with mutations L452R and N501Y. Recombinant protein expressed in Expi293 cells and Streptactin-purified. The protein is equipped with a SpyTag (AHIVMVDAYKPTK) at the C-terminus.

Variant of the SARS-CoV-2 receptor binding domain (aa 319-591) with mutations E484K and N501Y. Recombinant protein expressed in Expi293 cells and Streptactin-purified. The protein is equipped with a SpyTag (AHIVMVDAYKPTK) at the C-terminus.

Recombinant receptor binding domain (aa 319-591) of SARS-CoV-2 Gamma variant (mutations: K417T, E484K, N501Y) , expressed in Expi293 cells and Streptactin-purified. The protein is equipped with a SpyTag (AHIVMVDAYKPTK) at the C-terminus.

Recombinant receptor binding domain (aa 319-591) of SARS-CoV2 Omicron variant BA.1 (Mutations: G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A,  Q493K, G496S, Q498R, N501Y, Y505H, T547K), expressed in Expi293 cells and Streptactin-purified. The protein is equipped with a SpyTag (AHIVMVDAYKPTK) at the C-terminus.

Recombinant receptor binding domain (aa 319-591) of SARS-CoV2 Delta variant (mutations: L452R, T478K), expressed in Expi293 cells and Streptactin-purified. The protein is equipped with a SpyTag (AHIVMVDAYKPTK) at the C-terminus.

Influenza-A-Virus (H1N1), isolate "A/swine/Bakum/5/95" (RVB-0330), 2000, Germany

Cardiovirus A (Encephalomyocarditis virus 1, EMCV 1, RVB-0002), strain "LC 75 (Cuba)", Cuba 1982

Reverse genetics-based life cycle modelling system that allows modelling of Ebola virus genome replication and transcription, viral protein synthesis, virus assembly, budding, and Lloviu virus entry into target cells under BSL1 conditions.

Reverse genetics-based life cycle modelling system that can serve as negative control and is best used together with other trVLP systems that allows modelling of Ebola virus genome replication and transcription, viral protein synthesis, virus assembly, budding, and entry into target cells under BSL1 conditions.

Hybridoma cell culture supernatant containing anti-pan Orthobunyavirus antibodies; targeted antigen: Gc; clone: 6B2B2; immunization antigen: recombinant Gc Protein of LACV

anti-SARS-CoV-2 S protein (RBD, aa319-541) monoclonal antibody, clone 5E2B1

anti-SARS-CoV-2 S protein (S1 Ecto, aa1-1215) monoclonal antibody, clone 4B5C1

anti-SARS-CoV-2 S protein (NTD, aa17-304) monoclonal antibody, clone 6A5A3

Cowpox virus isolate DK05/15, "Amadeus", isolated from an horse abort in Germany in 2015

Hybridoma cell culture supernatant containing anti-Influenza A virus antibodies; targeted antigen: NA1; clone: 15.2.7.c; immunization antigen: several inactivated AIV H1Nx isolates

Hybridoma cell culture supernatant containing anti-Influenza A virus antibodies; targeted antigen: NA2; clone: 4.3.6; immunization antigen: several inactivated AIV HxN2 isolates

Hybridoma cell culture supernatant containing anti-Influenza A virus antibodies; targeted antigen: NA7; clone: 17.1.5; immunization antigen: several inactivated AIV HxN7 isolates

Hybridoma cell culture supernatant containing anti-Influenza A virus antibodies; targeted antigen: NP; clone: 11.1.5; immunization antigen: several inactivated AIV isolates

Hybridoma cell culture supernatant containing anti-Influenza A virus antibodies; targeted antigen: NS1; clone: 21.1.1.A; immunization antigen: several inactivated AIV isolates

Hybridoma cell culture supernatant containing anti-Influenza A virus antibodies; targeted antigen: Matrix Protein 1; clone: 4.2.1.A; immunization antigen: several inactivated AIV HxN2 isolates